风险提示：市场有风险，投资需谨慎。本文为AI大模型自动发布，任何在本文出现的信息（包括但不 限于个股、评论、预测、图表、指标、理论、任何形式的表述等）均只作为参考，不构成个人投资建 议。 浙商汇金量化臻选股票A（011824）成立日期2021年7月1日，最新规模6380.8万。今年以来收益 27.35%，同类排名2008/4220；近一年收益60.07%，同类排名1427/3820；成立以来收益17.12%。 浙商汇金量化臻选股票A（011824）基金经理为陈顾君。 截至发稿，陈顾君累计任职时间5年250天，现任基金资产总规模2.04亿元，任职期间最佳基金回报 35.77%， 任职期间最差基金回报-7.57%。 9月25日，振德医疗涨5.44%，截至发稿，报43.26元/股，成交1.35亿元，换手率1.20%，总市值115.27亿 元。 资料显示，振德医疗用品股份有限公司位于浙江省绍兴市越城区皋埠街道香积路55号，成立日期1994年 8月18日，上市日期2018年4月12日，公司主营业务涉及医用敷料的生产、研发与销售。主营业务收入构 成为：手术感控43.04%，基础护理20.46%，造口及现代伤口护理18.5 ...

Core Viewpoint - Zhendemedical experienced a 5.44% increase in stock price, reaching 43.26 CNY per share, with a trading volume of 135 million CNY and a turnover rate of 1.20%, resulting in a total market capitalization of 11.527 billion CNY [1] Company Overview - Zhendemedical is located in Shaoxing City, Zhejiang Province, and was established on August 18, 1994. The company went public on April 12, 2018. Its main business involves the production, research, and sales of medical dressings [1] - The revenue composition of Zhendemedical includes: - Surgical infection control: 43.04% - Basic care: 20.46% - Stoma and modern wound care: 18.59% - Pressure treatment and fixation: 10.75% - Infection control protection: 6.58% - Others: 0.58% [1] Shareholder Information - Zhendemedical's top circulating shareholder is a fund under China Merchants Fund, specifically the China Merchants Core Competitiveness Mixed A (014412), which increased its holdings by 581,000 shares in the second quarter, totaling 3.4286 million shares, representing 1.29% of circulating shares. The estimated floating profit today is approximately 7.6459 million CNY [2] - The China Merchants Core Competitiveness Mixed A fund was established on April 13, 2022, with a current scale of 2.993 billion CNY. Year-to-date returns are 22.19%, ranking 4235 out of 8173 in its category; the one-year return is 47.73%, ranking 3179 out of 8003; and since inception, the return is 58.91% [2] Fund Manager Information - The fund manager of China Merchants Core Competitiveness Mixed A is Zhu Hongyu, who has a cumulative tenure of 14 years and 133 days. The total asset scale of the fund is 4.964 billion CNY, with the best fund return during his tenure being 57.72% and the worst being -12.86% [3] Fund Holdings - Another fund under China Merchants Fund, the China Merchants Social Responsibility Mixed A (018309), holds 1.367 million shares of Zhendemedical, accounting for 2.96% of the fund's net value, making it the tenth largest holding. The estimated floating profit today is approximately 3.0484 million CNY [4] - The China Merchants Social Responsibility Mixed A fund was established on April 26, 2023, with a current scale of 974 million CNY. Year-to-date returns are 29.77%, ranking 3226 out of 8173; the one-year return is 54.04%, ranking 2634 out of 8003; and since inception, the return is 10.28% [4] Fund Manager Information (Social Responsibility Fund) - The fund manager of China Merchants Social Responsibility Mixed A is also Zhu Hongyu, with the same cumulative tenure and asset scale as mentioned previously [5]

截至2025年9月22日收盘，奥美医疗(002950)报收于9.47元，下跌0.73%，换手率0.89%，成交量4.04万 手，成交额3825.94万元。 董秘最新回复 投资者： 实控人是时候考虑换赛道突破发展了，通过资产重组或低价收购有前景资产的方式来寻求突 破？ 董秘： 尊敬的投资者您好！公司未来的主要并购方向为大健康行业，公司尤其注重协同效应与产业整 合。并购已纳入公司管理层的发展战略考量范畴，但需清醒认知到，并购对企业而言亦属于高风险行 为，因此公司对此持较为审慎的态度。感谢您对公司关注！ 投资者： 公司未来是否考虑并购重组，通过技术创新或低价收购有前景资产的方式来寻求突破发展？ 董秘： 尊敬的投资者您好！公司未来的主要并购方向为大健康行业，公司尤其注重协同效应与产业整 合。感谢您对公司关注！ 投资者： 同行的振德市值已突破百亿，将近是奥美的2倍，反观奥美市值持续锐减，60亿也难保，请问 董事长，公司出了什么问题？如何维护公司的形象？ 董秘： 尊敬的投资者您好！公司经营正常。二级市场价格受多种因素影响。感谢您的关注！ 投资者： AI芯片领域发展，市值千亿起步。人形智能机器人领域发展，市值百亿起步。就看 ...

Group 1 - The core viewpoint of the news is the performance and financial metrics of Zhendemedical, which saw a stock price increase of 5.08% to 37.45 CNY per share, with a trading volume of 1.007 billion CNY and a turnover rate of 10.47%, leading to a total market capitalization of 9.979 billion CNY [1] - Zhendemedical, established on August 18, 1994, and listed on April 12, 2018, specializes in the production, research, and sales of medical dressings, with its main business revenue composition being: surgical infection control 43.04%, basic care 20.46%, ostomy and modern wound care 18.59%, pressure treatment and fixation 10.75%, infection control protection 6.58%, and others 0.58% [1] Group 2 - From the perspective of major fund holdings, Xiangcai Fund has a significant position in Zhendemedical, with its Xiangcai Medical Health Mixed A Fund (019958) increasing its holdings by 10,000 shares to a total of 40,000 shares, representing 4.59% of the fund's net value, ranking as the eighth largest holding [2] - The Xiangcai Medical Health Mixed A Fund (019958) was established on December 26, 2023, with a latest scale of 13.2808 million CNY, achieving a year-to-date return of 50.36%, ranking 846 out of 8246 in its category, and a one-year return of 67.97%, ranking 1687 out of 8054 [2] Group 3 - The fund manager of Xiangcai Medical Health Mixed A Fund is Zhang Quan, who has been in the position for 1 year and 265 days, managing total assets of 18.3775 million CNY, with the best fund return during his tenure being 74.42% and the worst being 73.66% [3]

数据来源：中国海关，智研咨询整理 知前沿，问智研。智研咨询是中国一流产业咨询机构，十数年持续深耕产业研究领域，提供深度产业研 究报告、商业计划书、可行性研究报告及定制服务等一站式产业咨询服务。专业的角度、品质化的服 务、敏锐的市场洞察力，专注于提供完善的产业解决方案，为您的投资决策赋能。 相关报告：智研咨询发布的《2025-2031年中国医用敷料产业发展态势及市场发展策略报告》 根据中国海关数据显示：2025年7月中国医用敷料出口数量为2.54万吨，同比增长5%，出口金额为2.01 亿美元，同比增长4.5%。 近一年中国医用敷料出口情况统计图 ...

近期，振德医疗备受市场关注的是，公司被"钢铁大亨"孙纪木"举牌"。 9月10日晚间，振德医疗发布公告，公司控股股东浙江振德控股有限公司（简称"浙江振德"）及其全资子公司拟将 合计所持公司5%的股权转让给孙纪木，转让价款总计3.56亿元。 长江商报消息 ●长江商报记者 沈右荣 股价再涨停，振德医疗（603301.SH）上演了4天3板的大涨一幕。 9月12日，在A股市场，振德医疗股价高开高走，开盘4分钟涨停。这是其近4个交易日内收出的第三个涨停板。 这次交易，市场关注的不是控股股东以协议转让方式减持，而是受让方孙纪木。 孙纪木是知名"钢铁大亨"，其是河北新华联合冶金控股集团有限公司（简称"新华联合冶金控股"）的掌舵人。新 华联合冶金控股以超1700亿元的营业收入位列"2025中国民营企业500强"第42位。 孙纪木为何看上了振德医疗？振德医疗及孙纪木方面均未披露。 振德医疗主要从事医用敷料的生产、研发与销售，公司产品覆盖全球70多个国家和地区。近年来，公司来自海外 市场收入占比60%左右。 孙纪木拟出资3.56亿入股 超出市场预期，孙纪木入股了振德医疗。 9月10日晚，振德医疗发布公告，当日，公司控股股东浙江振德 ...

Group 1 - The core viewpoint of the news is that Zhendemedical has seen a stock price increase of 5.5%, reaching 31.07 yuan per share, with a total market capitalization of 8.279 billion yuan [1] - Zhendemedical, established on August 18, 1994, specializes in the production, research, and sales of medical dressings, with its main business revenue composition being: surgical infection control 43.04%, basic care 20.46%, stoma and modern wound care 18.59%, pressure treatment and fixation 10.75%, infection control protection 6.58%, and others 0.58% [1] Group 2 - Xiangcai Fund has a significant holding in Zhendemedical, with its Xiangcai Medical Health Mixed A Fund (019958) increasing its stake by 10,000 shares in the second quarter, bringing the total to 40,000 shares, which represents 4.59% of the fund's net value [2] - The Xiangcai Medical Health Mixed A Fund has achieved a year-to-date return of 49.12%, ranking 615 out of 8175 in its category, and a one-year return of 65.21%, ranking 1546 out of 7982 [2]

截至发稿，振德医疗市值为78亿元。 每经头条（nbdtoutiao）——"史上最丑"与"丑上最薄"：iPhone 17系列背后的新战事 （记者 张明双） 每经AI快讯，振德医疗（SH 603301，收盘价：29.45元）9月10日晚间发布公告称，公司于2025年9月10 日收到控股股东浙江振德及其全资子公司许昌园林的通知，浙江振德、许昌园林于2025年9月10日与孙 纪木、工行绍兴分行签署了《股份转让协议》，浙江振德、许昌园林拟将其持有的合计约1332万股无限 售条件流通股（占公司总股本5%）通过协议转让的方式以人民币26.74元/股的价格转让给孙纪木（其中 浙江振德拟转让约155万股，占公司总股本的0.58%；许昌园林拟转让约1177万股，占公司总股本的 4.42%），转让价款共计人民币约3.56亿元。本次协议转让不触及要约收购，不会导致公司控股股东及 实际控制人发生变化，受让方与公司控股股东及其一致行动人不存在关联关系。本次协议转让的交易背 景和目的转让方基于自身发展与资金安排通过协议转让方式减持公司股份，同时引入看好公司未来发展 前景的投资者。受让方基于对公司发展前景和长期投资价值的充分认可，拟通过协议 ...

Core Insights - The report by Zhiyan Consulting highlights the growth trajectory of China's medical dressing industry from 2025 to 2031, indicating a positive market outlook [1] Export Data Summary - In June 2025, China's medical dressing exports reached 25,600 tons, marking a year-on-year increase of 9.9% [1] - The export value for the same period was $20.1 million, reflecting a year-on-year growth of 8.7% [1] Company Profile - Zhiyan Consulting is recognized as a leading industry consulting firm in China, specializing in in-depth industry research and providing comprehensive consulting services, including feasibility studies and customized reports [1]

Core Viewpoint - Aomei Medical (002950) reported a solid performance in its 2025 mid-year financial results, with revenue and net profit showing significant year-on-year growth, indicating improved profitability and operational efficiency [1][3]. Financial Performance Summary - Total revenue for the first half of 2025 reached 1.676 billion yuan, a year-on-year increase of 5.99% [1]. - Net profit attributable to shareholders was 200 million yuan, up 6.87% from the previous year [1]. - In Q2 2025, total revenue was 918 million yuan, reflecting a 9.87% increase year-on-year, while net profit for the quarter was 113 million yuan, a rise of 21.71% [1]. - Gross margin improved to 29.64%, an increase of 2.83% year-on-year, and net margin rose to 12.13%, up 2.46% [1]. - Total expenses (selling, administrative, and financial) amounted to 170 million yuan, accounting for 10.17% of revenue, a decrease of 14.6% year-on-year [1]. Key Financial Metrics - Earnings per share (EPS) increased to 0.32 yuan, a growth of 6.33% [1]. - Cash flow from operating activities showed a 5.45% increase, attributed to higher revenue [5]. - The company’s cash and cash equivalents increased significantly by 123.29%, driven by revenue growth and the redemption of financial products [8]. Cost and Expense Analysis - Operating costs rose by 4.77%, primarily due to increased revenue [3]. - Selling expenses surged by 17.59%, linked to higher employee compensation and bonuses resulting from increased revenue [3]. - Administrative expenses decreased by 5.15% due to cost-cutting measures [4]. - Financial expenses saw a dramatic decline of 191.42%, attributed to foreign exchange gains from fluctuations in the RMB/USD exchange rate [4]. Investment and Return Metrics - The company’s return on invested capital (ROIC) was reported at 9.34%, indicating average capital returns [9]. - Historical data shows a median ROIC of 12.66% since the company’s listing, with the lowest ROIC recorded in 2023 at 3.23% [9]. - The company has emphasized its commitment to shareholder returns, with cumulative cash dividends amounting to approximately 1.099 billion yuan since 2018, exceeding the net raised funds by 2.29 times [9].